Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Prevalence of genetic variants associated with cardiac diseases in young out-of-hospital cardiac arrest (OHCA) patients in Pavia Province
Anno:
2025
Introduction: Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of mechanical cardiac activity evidenced by the lack of any systemic circulation signs, occurring outside a hospital. In young patients most of the OHCAs are attributable to structural or arrhythmogenic genetic-determined cardiomyopathies. A number of studies evaluated genetic variants in…
Leggi di più
Is “arrhythmogenic right ventricular dysplasia” the correct diagnosis for our patient?
Anno:
2025
A 71-year-old man labeled in the past as having “arrhythmogenic right ventricular dysplasia” was hospitalized in May 2022 for exacerbation of right-sided heart failure symptoms. He suffered from arterial hypertension and dyslipidemia, he was an ex-smoker and had family history of ischemic heart disease. In 2014 a slow-slow atrioventricular…
Leggi di più
Pediatric-onset of Scarring Cardiomyopathy in children affected by epidermolysis bullosa simplex with KLHL24 mutations
Anno:
2025
Background and aim:  Epidermolysis bullosa simplex (EBS) is a rare inherited blistering disease and mutations in kelch-like protein 24 (KLHL24) were recently implicated in a unique subtype of EBS [1,2]. KLHL24 is expressed at similar levels in keratinocytes and cardiomyocytes. There is a growing association of dilated cardiomyopathy in…
Leggi di più
THE RELATIONSHIP BETWEEN CARDIAC STRUCTURE, FUNCTION, AND CLINICAL OUTCOMES, AND THE IMPACT OF VUTRISIRAN FROM THE HELIOS-B TRIAL
Anno:
2025
Introduction: Transthyretin cardiomyopathy (ATTR-CM) is associated with high morbidity and mortality. Vutrisiran, an RNA interference therapeutic, rapidly knocks down circulating levels of TTR, thus suppressing the amyloid deposition that drives disease progression. In HELIOS-B, vutrisiran decreased risks of cardiovascular (CV) events and all-cause mortality (ACM) for patients with ATTR-CM….
Leggi di più
IMPACT OF BASELINE HEART FAILURE SEVERITY ON EFFICACY OF VUTRISIRAN IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY IN THE HELIOS-B TRIAL: A SUBGROUP ANALYSIS
Anno:
2025
Background: In the phase 3 HELIOS-B trial (NCT04153149), vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events, and improved functional capacity and quality of life (QoL) vs placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Methods: This subgroup analysis assessed the effect of vutrisiran…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram